Prenatal Care & Testing
NIPT Explained: What Non-Invasive Prenatal Testing Screens For
A clear, OB-reviewed guide to how cell-free DNA screening works, which chromosomal conditions it covers, when to do it, how accurate it is, and what a result—positive or not—actually means for your pregnancy.
Clinically reviewed · June 2026
NIPT is a blood test performed as early as 9 weeks that analyzes placental DNA circulating in the mother's bloodstream to screen for Down syndrome and other chromosomal differences. It is highly sensitive but is a screening tool, not a diagnosis — a positive result always requires confirmatory testing before any clinical decision is made.
When your provider mentions "cell-free DNA screening" or "NIPT" at your first prenatal visit, it can feel like a lot of unfamiliar language arriving at once. The test itself is simple — just a blood draw — but what it measures, what it can and cannot tell you, and how to interpret results deserve a clear, unhurried explanation. As an OB-GYN who discusses prenatal genetic testing with patients every day, I want to walk you through the science, the numbers, and the decisions in plain language.
This article is general educational information. It is not a substitute for a conversation with your own obstetrician, midwife, or genetic counselor, who can apply this information to your specific pregnancy.
How Does NIPT Work — What Is Cell-Free DNA?
During pregnancy, the placenta sheds small fragments of DNA into the mother's bloodstream. These fragments, called cell-free DNA (cfDNA), contain genetic material that reflects the chromosomal makeup of the pregnancy. NIPT works by drawing a small sample of maternal blood, isolating and sequencing all the cfDNA fragments present — both the mother's own DNA and the placental DNA — and then using computational analysis to detect whether any chromosomes appear in abnormal quantities.
The proportion of total cfDNA that comes from the placenta is called the fetal fraction. A fetal fraction of at least 4% is generally required for a reliable result; below that threshold, most labs report an inconclusive or "no-call" result and recommend redrawing at a later gestational age. By 9 to 10 weeks of gestation, fetal fraction is typically sufficient for testing in most pregnancies.
The three leading commercial NIPT laboratories use different technologies to analyze cfDNA. Natera Panorama uses a single-nucleotide polymorphism (SNP)-based approach that reads thousands of specific genetic positions simultaneously, allowing it to distinguish maternal from fetal DNA with particular precision — making it the only NIPT that can screen for triploidy and determine twin zygosity. Myriad Prequel uses a proprietary amplification method called Amplify that boosts the measurable fetal fraction, achieving the lowest published no-call rate (below 0.1%) of the three — an important advantage for individuals with elevated BMI, in whom low fetal fraction is more common. Labcorp MaterniT21 PLUS employs genome-wide counting across all 23 chromosome pairs and is the only test clinically validated for triplet or higher-order multiple pregnancies.
All three tests can be performed from a blood draw at 9 to 10 weeks, with results typically available within 7 to 14 calendar days.
What Conditions Does NIPT Screen For?
Every major NIPT covers the same core set of conditions. Understanding what each one means helps you read your report with clarity.
The three common trisomies — in which a fetus has three copies of a chromosome instead of the usual two — account for the majority of chromosomal conditions detected by NIPT:
- Trisomy 21 (Down syndrome) — the most common chromosomal condition in live births; associated with intellectual disability and a range of physical differences. NIPT detects it with approximately 99% sensitivity.
- Trisomy 18 (Edwards syndrome) — a severe chromosomal condition associated with complex organ differences; most affected pregnancies do not survive to term. NIPT detects it with 97–98% sensitivity.
- Trisomy 13 (Patau syndrome) — another severe condition associated with brain, heart, and kidney differences. NIPT sensitivity ranges from 91 to 100% in published studies, with false-positive rates below 0.2% for all three common trisomies.
Sex chromosome aneuploidies (SCAs) involve an abnormal number of X or Y chromosomes. All major NIPTs screen for monosomy X (Turner syndrome, 45,X), Klinefelter syndrome (47,XXY), 47,XYY, and 47,XXX. Importantly, the positive predictive value (PPV) for SCAs is considerably more variable than for common trisomies — monosomy X PPV in unselected populations ranges from only 20 to 29%, meaning most positive monosomy X results are false positives. This is one reason why confirmatory testing is always recommended.
Microdeletions are small missing segments of chromosomal material. The most clinically significant is 22q11.2 deletion syndrome (DiGeorge syndrome), associated with heart defects and immune differences, which all major panels include. ACOG has specifically noted that cfDNA screening for microdeletions has not been validated to the same standard as common trisomies, and that PPVs for rare microdeletions are considerably lower — making confirmatory testing even more important when a microdeletion is flagged.
Most panels also offer optional reporting of fetal sex, which is distinct from the chromosomal findings. You can request this information be withheld if you prefer to find out another way.
NIPT does not assess fetal anatomy, detect open neural tube defects, screen for single-gene disorders (such as cystic fibrosis or sickle cell disease — that is the role of carrier screening), or provide any information about the placenta or amniotic fluid. It is one piece of the prenatal information picture, not a comprehensive fetal assessment.
How Accurate Is NIPT — and What Does a Positive Result Actually Mean?
This is where the nuance matters most, and where patients are most often left confused by results letters that feel less clear than they should be.
NIPT is highly accurate in the sense of sensitivity: it catches the vast majority of affected pregnancies. A meta-analysis of more than 200,000 pregnancies found that NIPT detects over 99% of trisomy 21 pregnancies. That is substantially better than first-trimester combined screening (nuchal translucency plus bloodwork), which detects approximately 79–96% of Down syndrome pregnancies at a 3–5% false-positive rate.
However, the number that determines how worried you should be about a positive result is not sensitivity — it is positive predictive value (PPV): the probability that a positive test corresponds to a real chromosomal condition. PPV is governed by how common the condition is in the population being tested.
Because trisomy 21 is more common in live births than trisomy 13, and because maternal age raises baseline risk, PPV varies significantly:
| Condition | Approximate PPV Range | Clinical Implication |
|---|---|---|
| Trisomy 21 (Down syndrome) | 65–86% | Majority of positives are true; confirmatory testing recommended |
| Trisomy 18 | 35–58% | Meaningful false-positive rate; always confirm |
| Trisomy 13 | 18–25% | Majority of positives are false positives; confirmation essential |
| Monosomy X (Turner syndrome) | 20–29% | Most positives are false positives; CPM is common driver |
| Klinefelter syndrome (47,XXY) | 68–70% | Higher PPV among SCAs; confirmation still required |
Data from: PMC9261060, Positive predictive value estimates for noninvasive prenatal testing, PubMed Central.
Maternal age modifies PPV substantially. Women 35 and older have higher baseline chromosomal risk, so a positive NIPT carries more weight: in one large study, PPV for the combined common trisomies was 64.9% in women 35-plus versus 45.8% in younger women. In pregnancies with multiple compounding risk factors, combined T21/T18/T13 PPVs approached 97%.
The practical bottom line: a positive NIPT result is a signal that warrants follow-up, not a diagnosis. ACOG's 2026 Practice Advisory and the November 2025 SMFM Consult Series No. 74 both reinforce that patients should not make irreversible decisions based on a positive NIPT alone, without confirmatory diagnostic testing. CVS or amniocentesis — analyzed by chromosomal microarray — is the only path to a definitive answer.
When to Do NIPT, and What Happens After Results
NIPT is typically ordered at the first prenatal appointment, between 9 and 13 weeks. It requires only a standard blood draw — no needles near the uterus, no procedure-related miscarriage risk. Results arrive within one to two weeks and are reviewed by your provider, who can explain whether the result is low-risk (the most common outcome), high-risk (indicating possible chromosomal difference), or inconclusive (requiring a redraw).
If your result is low-risk, no further chromosomal workup is typically needed unless there are other clinical concerns such as an abnormal anatomy scan or elevated nuchal translucency measurement. A low-risk NIPT does not guarantee a chromosomally typical pregnancy — NIPT is a screening tool with sensitivity, not 100% certainty — but it substantially lowers probability of the conditions screened.
If your result is high-risk, your provider will discuss confirmatory diagnostic options. CVS can be performed from 10 to 13 weeks; amniocentesis from 15 weeks onward. Both retrieve fetal genetic material for chromosomal microarray analysis, which is now ACOG's recommended analytic method because it detects submicroscopic copy-number variants that a standard karyotype misses. Both carry a small but real procedure-related miscarriage risk (approximately 1 in 769 for amniocentesis and 1 in 455 for CVS in experienced hands, per ACOG Practice Bulletin No. 162). Your genetic counselor will help you weigh this against the probability that the NIPT finding is real.
On cost and insurance: self-pay costs with manufacturer assistance programs typically fall under $300, but without coverage, bills can exceed $1,000 or more. Coverage has improved: Cigna and Aetna now cover NIPT for all pregnant individuals regardless of age. Other insurers may still require a documented indication. Call your insurer before the blood draw, and ask your provider's office which laboratory is in-network.
All three major laboratories — Natera, Myriad Genetics, and Labcorp — provide free access to board-certified genetic counselors, which is worth using regardless of your result. Genetic counselors are trained to translate screening statistics into the context of your specific pregnancy, age, and history in a way that a brief provider appointment often cannot fully cover.
Frequently asked
When can NIPT be done during pregnancy?
NIPT can be performed as early as 9 to 10 weeks of gestation — earlier than any other prenatal chromosomal screen. All three leading commercial tests (Natera Panorama, Myriad Prequel, and Labcorp MaterniT21 PLUS) become reliably performable at this point because placental DNA circulating in maternal blood reaches a measurable concentration, called the fetal fraction, by then. Results typically return within 7 to 14 calendar days of the blood draw. In practice, most providers order NIPT at the first prenatal visit, which usually falls between 8 and 10 weeks. This article is general educational information, not medical advice — talk with your OB or midwife about the timing that fits your pregnancy.
What chromosomal conditions does NIPT screen for?
Every major NIPT screens for the three most common trisomies: trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). All tests also screen for sex chromosome aneuploidies including monosomy X (Turner syndrome), Klinefelter syndrome (47,XXY), and 47,XYY, plus optional fetal sex reporting. Most panels now include a selection of microdeletions, with ACOG noting that microdeletion PPVs are considerably lower than those for common trisomies, so confirmatory testing is especially important for a positive microdeletion result. Natera Panorama is uniquely able to screen for triploidy and can determine twin zygosity, while Labcorp MaterniT21 PLUS is the only validated option for triplet or higher-order pregnancies.
How accurate is NIPT — and what does a positive result actually mean?
NIPT is highly sensitive: published data across more than 68,000 pregnancies cite sensitivity of approximately 99% for trisomy 21, 97–98% for trisomy 18, and 91–100% for trisomy 13, with false-positive rates below 0.2% for the common trisomies. However, sensitivity and positive predictive value (PPV) are different things. PPV — the probability that a positive result reflects a real chromosomal difference — varies by condition and maternal age. In one laboratory-based PPV analysis, PPV was 86% for trisomy 21 but only 25% for trisomy 13; monosomy X PPV ranged from just 20–29%. This means a significant proportion of positive NIPT results are false positives, particularly for rarer conditions. A positive NIPT is never a diagnosis — confirmatory testing with CVS or amniocentesis is always recommended before any clinical decision is made.
How much does NIPT cost, and does insurance cover it?
None of the major NIPT laboratories publishes a universal list price. When a manufacturer's financial-assistance program is applied, self-pay costs typically fall under $300; without coverage, patients have reported bills exceeding $1,000 to $1,500, and in extreme cases much more following insurance denial. Coverage varies by payer. Cigna and Aetna now cover NIPT for all pregnant individuals without age restriction; other insurers still require a documented clinical indication such as advanced maternal age or an abnormal prior screen. ACOG maintains an active toolkit advocating to close coverage gaps for NIPT in average-risk pregnancies. All three major labs (Natera, Myriad, Labcorp) offer free board-certified genetic counseling to help patients interpret results and navigate billing. Always call your insurer before your blood draw to confirm your specific benefit.
What causes a false positive on NIPT?
False positives on NIPT have several well-understood biological sources. The most common is confined placental mosaicism (CPM) — a chromosomally abnormal cell line present only in the placenta, not in the fetus, because NIPT reads placental DNA rather than fetal DNA directly. Additional sources include maternal chromosomal variants, maternal somatic mosaicism, a vanishing twin (a co-twin reabsorbed early in pregnancy that continues to shed DNA), and — rarely — an undiagnosed maternal malignancy, whose circulating tumor DNA can mimic a chromosomal signal. Maternal BMI also matters: a nine-year study of 38,160 NIPT results found that fetal fraction fell progressively with higher BMI, which was associated with significantly elevated false-positive rates, especially for monosomy X. This is one reason ACMG recommends confirmatory invasive testing after any positive NIPT result.
Is NIPT recommended for everyone, or only high-risk pregnancies?
As of 2020 and reaffirmed in updated SMFM guidance published in November 2025, ACOG and SMFM recommend that NIPT be offered to all pregnant individuals, regardless of age or baseline risk — moving away from the prior practice of restricting it to women 35 and older. However, ACOG also specifies that only one screening approach should be used per pregnancy: layering NIPT on top of first-trimester combined screening (nuchal translucency plus bloodwork) produces discordant results and an unacceptably high cumulative false-positive rate. If you choose NIPT, you generally do not also need the NT+bloodwork screen. Discuss with your provider which approach fits your clinical picture, insurance coverage, and the gestational timing of your prenatal care.
How do Natera Panorama, Myriad Prequel, and Labcorp MaterniT21 PLUS compare?
All three tests cover the same core conditions (trisomies 21, 18, 13; sex chromosome aneuploidies; common microdeletions; optional fetal sex) from a blood draw at 9–10 weeks. Their technology and specific strengths diverge. Natera Panorama uses SNP-based sequencing — the only NIPT that screens for triploidy and determines twin zygosity. Myriad Prequel uses proprietary Amplify technology that boosts measurable fetal fraction, achieving a no-call rate below 0.1% — the lowest in the category — which is particularly valuable for individuals with elevated BMI. Labcorp MaterniT21 PLUS is the only clinically validated NIPT for triplet or higher-order multiples and offers an Enhanced Sequencing Series (ESS) panel adding trisomies 16 and 22 plus seven microdeletion regions. All three provide free genetic counseling. Your provider and your insurance panel will often determine which test is ordered.